Keywords
Last Name
Institution

Carol A Sherman

Title
InstitutionMedical University of South Carolina
DepartmentMedicine
AddressP.O. Box MSC 635
102
173 Ashley Ave.
Phone843-792-4271
vCardDownload vCard

    Collapse Overview 
    Collapse keywords
    Stage III, Stage IV, Lung, Cancer, Cancer/Lung, Drug Studies

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704. PMID: 29628312.
      View in: PubMed
    2. Dimou A, Sherman C, Wrangle J. Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. J Thorac Imaging. 2016 Jul; 31(4):238-42. PMID: 27306389.
      View in: PubMed
    3. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015 Feb; 10(2):232-6. PMID: 25526238.
      View in: PubMed
    4. Tanner NT, Sherman CA, Silvestri GA. Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. Transl Lung Cancer Res. 2012 Jun; 1(2):96-8. PMID: 25806163.
      View in: PubMed
    5. Tanner NT, Pastis NJ, Sherman C, Simon GR, Lewin D, Silvestri GA. The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012 May; 76(2):131-7. PMID: 22176813.
      View in: PubMed
    6. Watkins JM, Zauls AJ, Kearney PL, Shirai K, Ruppert BN, Harper JL, Sherman CA, Aguero EG, Reed CE, Sharma AK. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Jpn J Clin Oncol. 2011 Mar; 41(3):334-42. PMID: 21084436.
      View in: PubMed
    7. Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9. PMID: 20958948.
      View in: PubMed
    8. Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52. PMID: 19841574.
      View in: PubMed
    9. Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT, Sharma AK. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun; 28(5):340-8. PMID: 20585921.
      View in: PubMed
    10. Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1108-13. PMID: 19084345.
      View in: PubMed
    11. Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231. PMID: 18096059.
      View in: PubMed
    12. Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221. PMID: 18053191.
      View in: PubMed
    13. Urbanic JJ, Turrisi AT, Sharma AK, Silvestri GA, Williams TE, Vanek KN, Sherman CA. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol. 2006 Feb; 1(2):112-9. PMID: 17409839.
      View in: PubMed
    14. Sherman CA, Herndon JE, Watson DM, Green MR. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004 Sep; 45(3):387-92. PMID: 15301880.
      View in: PubMed
    15. Rocha Lima CM, Catapano CV, Pacheco D, Sherman CA, Oakhill G, Mushtaq C, Freeman KD, Green MR. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Cancer. 2004 Jun 15; 100(12):2671-9. PMID: 15197811.
      View in: PubMed
    16. Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, Sherman C, Mikhitarian K, Cole DJ, Block MI, Gillanders WE. Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003 Nov; 5(4):237-42. PMID: 14573783.
      View in: PubMed
    17. Turrisi AT, Bogart J, Sherman C, Silvestri G. The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease. Respir Care Clin N Am. 2003 Jun; 9(2):163-90. PMID: 12911288.
      View in: PubMed
    18. Frizzell B, Sinha D, Williams T, Reed CE, Sherman CA, Turrisi A. Influence of celiac axis lymph nodes in the definitive treatment of esophageal cancer. Am J Clin Oncol. 2003 Jun; 26(3):215-20. PMID: 12796587.
      View in: PubMed
    19. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6. PMID: 12733147.
      View in: PubMed
    20. Sherman CA, Turrisi AT, Wallace MB, Reed CE. Locally advanced esophageal cancer. Curr Treat Options Oncol. 2002 Dec; 3(6):475-85. PMID: 12392637.
      View in: PubMed
    21. Silvestri GA, Sherman C, Williams T, Leong SS, Flume P, Turrisi A. Caring for the dying patient with lung cancer. Chest. 2002 Sep; 122(3):1028-36. PMID: 12226050.
      View in: PubMed
    22. Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Green MR. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):19-24. PMID: 12109801.
      View in: PubMed
    23. Turrisi AT, Sherman CA. The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer. 2002 Jan; 38(2):279-91. PMID: 11803144.
      View in: PubMed
    24. Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):46-51. PMID: 11301841.
      View in: PubMed
    25. Rocha Lima CM, Urbanic JJ, Sherman CA, Brescia FJ, Green MR. Docetaxel followed by gemcitabine and irinotecan in solid tumors. Oncology (Williston Park). 2001 Jan; 15(1 Suppl 1):37-45. PMID: 11221020.
      View in: PubMed
    26. Green MR, Harper M, Safa A, Sherman CA, Mushtaq CM, Bahadori H, Brescia FJ, Rocha Lima CM. Irinotecan in the management of patients with pancreatic cancer. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):31-3. PMID: 11200146.
      View in: PubMed
    27. Sherman CA, Rocha Lima CM, Turrisi AT. Limited small-cell lung cancer: a potentially curable disease. Oncology (Williston Park). 2000 Oct; 14(10):1395-403; discussion 1403-4, 1409. PMID: 11098505.
      View in: PubMed
    28. Green MR, Rocha Lima CM, Sherman CA. Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol. 2000 Oct; 10(4):289-95. PMID: 11040329.
      View in: PubMed
    29. Cappuzzo F, Rocha Lima CM, Sherman CA, Green MR. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):7-14. PMID: 10960939.
      View in: PubMed
    30. Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PMID: 10585008.
      View in: PubMed
    31. Leong SS, Rocha Lima CM, Sherman CA, Green MR. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest. 1999 Jan; 115(1):242-8. PMID: 9925091.
      View in: PubMed
    Sherman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _